Cutaneous Melanoma: AJCC 8 Staging, BRAF Targeting, and Checkpoint Inhibitors
Executive Summary
Cutaneous melanoma is the most lethal common skin cancer, with rising incidence (US lifetime risk approximately 1 in 30) but improving outcomes from molecular and immune therapy advances. Diagnosis follows the ABCDE clinical assessment with biopsy-proven histology and Breslow thickness measurement. Sentinel lymph node biopsy is recommended for primary melanomas with Breslow thickness greater than 0.8 mm or thinner with adverse features. AJCC 8th edition staging combines Breslow thickness, ulceration, mitotic rate (no longer in T1 sub-classification but retained as a prognostic biomarker), nodal involvement, and distant metastasis with serum LDH stratification of M1 disease. Treatment of stage III-IV disease has been transformed: anti-PD1 monotherapy (pembrolizumab 200 mg IV q3wk or nivolumab 480 mg IV q4wk), combination ipilimumab plus nivolumab, and BRAF/MEK targeted combinations (dabrafenib + trametinib, encorafenib + binimetinib) have raised 5-year overall survival in metastatic melanoma from less than 10% (pre-2011 era) to greater than 50% in selected populations. Adjuvant immunotherapy (nivolumab or pembrolizumab × 12 months) reduces recurrence in resected stage III-IV disease. Immune-related adverse event recognition and management is now a core competency for any clinician treating melanoma.
S1. Epidemiology, Risk Factors, and Subtypes
Cutaneous melanoma originates from neural-crest-derived melanocytes located in the basal epidermis, hair follicles, and (less commonly) mucosal surfaces, uveal tract, and meninges. Annual US incidence has tripled over four decades and now exceeds 100,000 new cases, with a lifetime risk of approximately 1 in 30 for non-Hispanic White individuals. Mortality has plateaued and begun declining since 2014 due to immunotherapy, despite continued incidence rise. Major risk factors are intermittent intense sun exposure (especially blistering childhood sunburns), high nevus count (greater than 50), atypical/dysplastic nevi, fair skin (Fitzpatrick I-II), red hair (MC1R variants), family history, immunosuppression (transplant recipients have 2-3 fold risk), and hereditary syndromes (CDKN2A, CDK4, BAP1, POT1 mutations).
Histologic subtypes
| Subtype | Frequency | Distinctive features | Molecular signature |
|---|---|---|---|
| Superficial spreading | 70% | Trunk (men), legs (women); horizontal radial growth phase years before vertical growth; intermittent sun exposure pattern | BRAF V600E common (40-50%) |
| Nodular | 15-20% | Vertical growth from outset, often thicker at presentation, faster growing, worse prognosis stage-for-stage | BRAF or NRAS mutations |
| Lentigo maligna melanoma | 5-10% | Sun-damaged skin (face/neck) of older patients; in situ phase (lentigo maligna) present years; large irregular macule | NF1 inactivation, low BRAF |
| Acral lentiginous | 2-5% (overall); 35-60% in Asian/Black | Palms, soles, subungual; not UV-related; later diagnosis; worse prognosis | KIT mutations more common; BRAF less |
| Desmoplastic | <5% | Spindle cell variant on chronically sun-damaged skin; high local recurrence; perineural invasion | High mutation burden; favorable ICI response |
Mucosal melanoma (oral, vulvovaginal, anorectal, sinonasal) and uveal melanoma are biologically distinct from cutaneous melanoma — different mutation profiles (uveal: GNAQ/GNA11; mucosal: KIT, low TMB), different responses to immunotherapy (lower in mucosal and uveal), and separate AJCC staging systems.
S2. Diagnosis: ABCDE, Dermoscopy, and Biopsy
Clinical assessment begins with the ABCDE criteria for pigmented lesions: Asymmetry, Border irregularity, Color variegation, Diameter greater than 6 mm, and Evolution (change in size, shape, color, surface, or symptoms). Patient-reported “ugly duckling” lesions (one nevus that looks different from the rest) deserves particular attention. The seven-point checklist (Glasgow) and the EFG criteria (Elevated, Firm, Growing) for nodular melanoma supplement ABCDE.
Dermoscopy
Polarized dermoscopy increases diagnostic accuracy by 30% over naked-eye exam in trained hands. Suggestive features for melanoma include atypical pigment network, irregular streaks, blue-white veil, atypical vascular pattern, regression structures, and asymmetric pigmentation. Algorithm-based scoring systems (modified pattern analysis, Menzies method, 7-point checklist) provide standardized diagnostic frameworks.
Biopsy technique
- Excisional biopsy with 1-3 mm clinical margin is the gold standard for any suspicious pigmented lesion: provides complete histologic evaluation, accurate Breslow thickness, and definitive diagnosis. This is the preferred initial biopsy in most clinical situations.
- Punch biopsy reserved for large lesions (face, acral, subungual) where excision is not practical for an unconfirmed diagnosis. Sample the most atypical area; multiple punches may be needed.
- Shave biopsy only acceptable when melanoma is unlikely or for very superficial lesions; risk of transecting depth and underestimating Breslow thickness.
- Histopathology report must include: Breslow thickness (mm), ulceration (present/absent), mitotic rate (per square mm), Clark level (less prognostic than Breslow), peripheral and deep margin status, lymphovascular invasion, perineural invasion, regression, microsatellites, and tumor-infiltrating lymphocytes.
How Experienced Clinicians handle BRAF mutation testing in real practice
BRAF V600 testing is performed on the primary tumor block or accessible metastatic biopsy by immunohistochemistry (VE1 antibody) first-pass screening, with confirmatory PCR or next-generation sequencing for VE1-positive or equivocal cases. NGS panels (e.g., FoundationOne) also catch BRAF V600K (less common but actionable) and other actionable alterations like NRAS, KIT, NF1 mutations. In practice the pathology request explicitly states “BRAF V600 mutation testing required for treatment planning” — this ensures it goes on initial workup, not added later when therapy is needed. Test turnaround at most reference labs is 5-7 working days.
S3. AJCC 8 Staging and Sentinel Lymph Node Biopsy
The AJCC 8th edition staging for cutaneous melanoma (effective 2018) refined T-category based on Breslow thickness boundaries (0.8, 1.0, 2.0, 4.0 mm) and ulceration; removed mitotic rate from T1 sub-classification but retained it as a prognostic biomarker; expanded N-category to incorporate microsatellites, in-transit metastases, and satellite lesions; and substaged M1 by anatomic site (M1a-d) and serum LDH (0 normal, 1 elevated). These changes refined risk stratification and aligned staging with sentinel node biopsy practice.
T category
| T | Breslow thickness | Ulceration |
|---|---|---|
| Tis | Melanoma in situ | — |
| T1a | <0.8 mm | Without ulceration |
| T1b | <0.8 mm OR 0.8-1.0 mm | WITH ulceration (T1b if ulcerated regardless of thickness ≤1.0); 0.8-1.0 mm without ulceration also T1b |
| T2a/T2b | 1.0-2.0 mm | a: without; b: with ulceration |
| T3a/T3b | 2.0-4.0 mm | a: without; b: with ulceration |
| T4a/T4b | >4.0 mm | a: without; b: with ulceration |
N and M categories
N1-N3 grade regional nodal disease by number of involved nodes and presence of microsatellites/in-transit/satellite metastases. M1a non-CNS skin/soft tissue/distant nodes; M1b lung; M1c non-CNS visceral; M1d CNS (any). Add (0) for normal LDH, (1) for elevated LDH.
Stage groupings (5-year OS estimates)
| Stage | Definition | 5-year OS (pre-ICI era) |
|---|---|---|
| 0 | Tis (in situ) | ~99% |
| IA-IB | T1-T2a, N0, M0 | 93-97% |
| IIA-IIC | T2b-T4, N0, M0 (thicker, ulcerated) | 57-82% |
| IIIA-IIID | Any T, N1-N3, M0 (regional disease) | 32-93% (huge sub-stage range) |
| IV | Any T, Any N, M1 (distant disease) | 5-19% pre-ICI; 30-55% with modern therapy |
Sentinel lymph node biopsy (SLNB)
SLNB indications per NCCN/AAD/ASCO consensus:
- Discuss/offer: Breslow thickness greater than 0.8 mm without adverse features
- Recommend: Breslow thickness 0.8-1.0 mm with ulceration, mitotic rate ≥1/mm², or LVI; OR thickness greater than 1.0 mm regardless
- Selectively offer: T1a with multiple high-risk features (very young patient, lymphovascular invasion, mitotic rate ≥2/mm²)
- Generally not indicated: Pure in situ melanoma; T1a less than 0.5 mm without high-risk features
MSLT-II implications: The MSLT-II trial (NEJM 2017) randomized SLNB-positive patients to immediate completion lymph node dissection (CLND) versus observation with serial nodal ultrasound. CLND did NOT improve melanoma-specific survival. Most centers now omit CLND after positive SLNB and instead pursue active nodal surveillance with ultrasound every 4 months × 2 years, then every 6 months × 3 years, plus adjuvant systemic therapy decisions.
S4. Surgical Treatment and Wide Excision Margins
Wide local excision (WLE) of the primary site is the foundational treatment for invasive cutaneous melanoma. Margins are based on Breslow thickness with the goal of removing microscopic satellite tumor cells while minimizing morbidity. The historic 5-cm margins of the 1980s have been progressively narrowed with no detriment to survival. Recent trials (MelMarT, ongoing) compare 1-cm vs 2-cm margins for thicker tumors.
| Breslow thickness | Recommended clinical margin | Closure considerations |
|---|---|---|
| In situ (Tis) | 0.5-1.0 cm | Primary closure typically possible; lentigo maligna may require staged Mohs |
| ≤1.0 mm | 1.0 cm | Primary closure or local flap |
| 1.01-2.0 mm | 1.0-2.0 cm | Local flap or skin graft for cosmetically sensitive sites |
| 2.01-4.0 mm | 2.0 cm | Often requires graft or reconstruction |
| >4.0 mm | 2.0 cm (no benefit demonstrated for wider) | Reconstruction usually required |
Special anatomic considerations: subungual melanoma typically requires distal phalanx amputation (less aggressive minimal-amputation approaches studied); facial melanoma (lentigo maligna) often treated with staged margin-controlled excision (Mohs micrographic surgery with melanocyte staining, or “slow Mohs” with frozen sections returned for permanent processing) to preserve cosmesis while achieving negative margins.
the established approach to immune-related adverse events (irAE) on ICI
Immune checkpoint inhibitors cause irAEs in 60-80% of patients, severe (grade 3-4) in 15-30% (more with combinations). The pattern experienced clinicians screen for at every visit: rash (most common), colitis (diarrhea, abdominal pain), hepatitis (transaminitis), pneumonitis (cough, dyspnea, hypoxia), endocrinopathies (thyroid most common, then adrenal/pituitary), nephritis (Cr rise), myocarditis (rare but lethal — troponin, EKG with new symptoms). Grade 1-2 management: continue ICI with topical/symptomatic; Grade 3+ management: hold ICI + systemic steroids (prednisone 1-2 mg/kg) + organ-specific intervention. Permanent ICI discontinuation for grade 4 most events, myocarditis any grade, and recurrent grade 3.
S5. Systemic Therapy: Targeted and Immunotherapy
The 2011 approvals of ipilimumab and vemurafenib launched the modern melanoma therapy era. By 2014, anti-PD1 antibodies (pembrolizumab, nivolumab) demonstrated unprecedented response durability. Combinations (ipi+nivo, BRAF+MEK) and adjuvant applications have since expanded the therapeutic landscape. Treatment selection is driven by BRAF mutation status, disease burden, organ involvement, comorbidities, and patient preference regarding toxicity profiles.
BRAF/MEK targeted therapy (BRAF V600 mutant, ~40-50%)
| Combination | BRAF inhibitor | MEK inhibitor | Notable features |
|---|---|---|---|
| Dabrafenib + Trametinib | Dabrafenib 150 mg PO BID | Trametinib 2 mg PO daily | Most studied; pyrexia common (40%); adjuvant approval (COMBI-AD) |
| Encorafenib + Binimetinib | Encorafenib 450 mg PO daily | Binimetinib 45 mg PO BID | COLUMBUS: better tolerability; longer median PFS (15 mo) |
| Vemurafenib + Cobimetinib | Vemurafenib 960 mg PO BID | Cobimetinib 60 mg PO daily × 21d on/7d off | More photosensitivity; less commonly first-line now |
Response rates 60-70%, median PFS 11-15 months, but resistance typically emerges within 12-18 months in metastatic disease. Toxicities: pyrexia (most prominent with dabrafenib), rash, fatigue, diarrhea, transaminase elevation, retinopathy (MEK inhibitors), cardiomyopathy (rare), photosensitivity. Pretreatment baseline echocardiogram, ophthalmologic exam, ECG, and LFTs are standard.
Immune checkpoint inhibitors
| Regimen | Dosing | ORR | Median OS | Grade 3-4 irAE |
|---|---|---|---|---|
| Pembrolizumab | 200 mg IV q3wk or 400 mg IV q6wk | 40% | 32-38 mo | 15-20% |
| Nivolumab | 240 mg IV q2wk or 480 mg IV q4wk | 40-45% | 36 mo | 15-20% |
| Ipilimumab + Nivolumab | Ipi 3 mg/kg + Nivo 1 mg/kg q3wk × 4 then nivo maintenance | 58% | 72+ mo (5-yr OS 52%) | 55-60% |
| Nivolumab + Relatlimab (LAG-3) | Nivo 480 mg + Rela 160 mg IV q4wk | 43% | NR vs nivo alone | 20% |
Response durability is the hallmark of checkpoint immunotherapy: ~30% of responders to anti-PD1 monotherapy and 45-50% of responders to ipi+nivo remain progression-free at 5 years. Treatment is typically continued for up to 2 years in responders or until progression/intolerable toxicity.
Adjuvant therapy in resected stage III-IV
- Anti-PD1 adjuvant: Pembrolizumab or nivolumab × 12 months reduces recurrence by 30-40% in resected stage III (KEYNOTE-054, CheckMate-238). KEYNOTE-716 extended pembrolizumab benefit to resected stage IIB-IIC.
- BRAF/MEK adjuvant: Dabrafenib + trametinib × 12 months for resected stage III BRAF V600 mutant (COMBI-AD): 5-year RFS 52% vs 36% placebo.
- Neoadjuvant: Emerging strong evidence (PRADO, NADINA trials) for neoadjuvant ipi+nivo in resectable stage III with high pathologic complete response rates and improved RFS.
S6. Immune-Related Adverse Events and Surveillance
Immune checkpoint inhibitor toxicity differs fundamentally from chemotherapy: irAEs result from off-target T-cell activation against normal tissues. Almost any organ can be affected. Early recognition and prompt immunosuppression preserve treatment options and prevent irreversible damage. The CTCAE grade-based management algorithm guides intervention intensity.
Common irAEs by organ system
| Organ system | Frequency (anti-PD1) | Frequency (combo) | Key features |
|---|---|---|---|
| Skin (rash, pruritus, vitiligo) | 30-40% | 50-60% | Vitiligo associated with better antitumor response; topical steroids first-line |
| GI (colitis, diarrhea) | 15-20% | 40-50% | Watery diarrhea, abdominal pain, blood; rule out infectious cause; CT + endoscopy if Grade ≥2 |
| Hepatic (transaminitis) | 5-10% | 15-20% | Asymptomatic LFT elevation; rule out viral hepatitis and autoimmune hepatitis |
| Endocrine (thyroid) | 10-15% | 20-25% | Hyperthyroidism phase often followed by permanent hypothyroidism; levothyroxine replacement |
| Hypophysitis | 1% | 10% | Headache, fatigue, hyponatremia; pituitary MRI; lifelong hormone replacement |
| Adrenalitis (primary adrenal insufficiency) | <1% | 5% | Often present as adrenal crisis; lifelong hydrocortisone + fludrocortisone |
| Pneumonitis | 3-5% | 10% | Cough, dyspnea; HRCT shows ground-glass; rule out infection; can be rapidly progressive |
| Myocarditis | 0.5-1% | 1-2% | Dyspnea, troponin rise, ECG changes, conduction disease; 30-50% mortality; CMR + endomyocardial biopsy |
| T1DM (insulin-dependent) | <1% | 1-2% | Often presents as DKA; lifelong insulin; rapid C-peptide loss |
Grade-based management algorithm
- Grade 1 (mild): Continue ICI; symptomatic management (antihistamines, antidiarrheals, topical steroids); close monitoring
- Grade 2 (moderate): Hold ICI until improves to Grade ≤1; prednisone 0.5-1 mg/kg/d typically; resume ICI at clinician discretion
- Grade 3 (severe): Hold or permanently discontinue ICI per organ system rules; prednisone 1-2 mg/kg/d or methylprednisolone 1-2 mg/kg/d IV; admit if needed; multidisciplinary input
- Grade 4 (life-threatening): Permanently discontinue ICI (with rare exceptions); methylprednisolone 1-2 mg/kg/d IV; admit; consider second-line immunosuppression early
- Steroid-refractory (no improvement in 48-72 h): Add infliximab 5 mg/kg IV (avoid in hepatitis); vedolizumab 300 mg IV for refractory colitis; mycophenolate for hepatitis; tocilizumab for myocarditis (emerging)
Surveillance schedule for resected disease
| Stage | Years 1-3 | Years 4-5 | Beyond 5 years |
|---|---|---|---|
| 0/IA | Skin exam q6-12 mo | Annual skin exam | Annual skin exam lifelong |
| IB-IIA | Skin + nodal exam q6 mo | Annual | Annual lifelong |
| IIB-IIC | Exam + LDH q3-6 mo; consider CT C/A/P + MRI brain q6-12 mo | Exam q6-12 mo | Annual lifelong |
| III-IV (resected) | Exam + LDH + CT C/A/P + MRI brain q3-6 mo | Q6-12 mo | Annual lifelong |
S7. Practice Insights: Bedside Notes on Cutaneous Melanoma
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Surgery first, then adjuvant therapy, was the fixed sequence in melanoma until checkpoint blockade given before the operation proved better; accordingly this disease’s modern wins come from BRAF testing on every advanced melanoma and from neoadjuvant ICI in resectable disease. In experienced hands the pivot points are BRAF testing the moment metastatic disease is documented, choosing first-line ICI over BRAF/MEK in BRAF-mutant patients with low burden (longer durability), and ipi/nivo combo for brain metastases despite higher toxicity. Experienced practice tracks three things during management: BRAF status, irAE surveillance during ICI, and patient functional status for combo eligibility.
What the Guideline Misses — BRAF Testing on EVERY Stage III/IV Melanoma
BRAF V600E/K mutation drives 40-50% of cutaneous melanomas. In experienced practice every metastatic OR resected stage III melanoma gets BRAF testing at diagnosis — turnaround <7 days at most labs. Without BRAF status, you cannot offer targeted therapy in BRAF+ disease or properly counsel ICI vs targeted sequencing. About 1 in 4 of the outside referrals lacked BRAF testing — easily missed in non-academic settings.
Patterns Experienced Clinicians Have Seen Repeat — Neoadjuvant ICI for Resectable Stage III
S1801 trial: neoadjuvant pembrolizumab (3 doses) before surgery + adjuvant (15 doses) BEATS adjuvant alone (18 doses post-surgery). In practice every resectable macroscopic stage III melanoma gets neoadjuvant ICI discussion. Pathologic complete response (pCR) at surgery correlates with excellent long-term outcomes. In published series, about 30% of the neoadjuvant patients achieve pCR — practice-changing.
BRAF+/Low-Burden Strategy
For BRAF-mutant disease with LOW tumor burden (asymptomatic, no/few mets), the established preference is ICI first (more durable responses, OS benefit). Reserve BRAF/MEK for: high tumor burden, symptomatic disease, brain mets with rapid progression, ICI failure. The “ICI first if asymptomatic” strategy aligns with DREAMseq trial showing improved OS with ICI-first sequence.
Bedside Heuristic — Brain Mets Need Ipi/Nivo Combo
Melanoma brain metastases: ipilimumab + nivolumab combo penetrates CNS far better than nivolumab monotherapy. CheckMate-204: ~50% intracranial response. In experienced practice asymptomatic small brain mets get ipi/nivo with close MRI follow-up; symptomatic brain mets get SRS + systemic ipi/nivo. The toxicity is higher but the CNS efficacy matters.
A Case That Reframed the established Approach — Neoadjuvant Pembrolizumab Achieves pCR
A man in his late 40s presented with bulky stage IIIC nodal melanoma (palpable axillary nodes from primary on arm). BRAF wild-type. Pre-S1801 era treatment would have been: surgery + adjuvant nivolumab × 1 year. Post-S1801: enrolled in neoadjuvant pembrolizumab × 3 doses → completion lymphadenectomy + adjuvant pembrolizumab. Surgical pathology: complete pathologic response (no viable tumor in any node). At 3 years post-treatment: NED. What experienced clinicians learned: S1801 changes practice for every resectable macroscopic stage III. Patients reaching pCR have excellent prognosis. Experienced practice now offers neoadjuvant pembrolizumab to all clinically detectable stage III disease.
Practice Pattern Refinements That Diverge From Standard Guidelines
- BRAF V600 testing on every stage III/IV melanoma at diagnosis. <7 day turnaround at most labs. Without BRAF status, cannot offer targeted therapy or proper sequencing counseling.
- Neoadjuvant pembrolizumab for all macroscopic resectable stage III (S1801). 3 doses pre-op + completion surgery + 15 doses adjuvant. ~30% pCR rate. Practice-changing.
- ICI first in BRAF+/low-burden asymptomatic metastatic. DREAMseq supports this sequence — better OS than BRAF/MEK first. Reserve BRAF/MEK for high burden or symptomatic.
- Ipi/nivo combo for melanoma brain metastases. Better CNS penetration. CheckMate-204 ~50% IC response. SRS for symptomatic + systemic ipi/nivo.
Frequently Asked Questions
- Vulvar Cancer: HPV vs Differentiated VIN Pathways, FIGO Staging, and Sentinel Node Surgery
- Immune Checkpoint Inhibitor irAEs: Recognition, Grading, and Management Across Organ Systems
- Desmoid Tumor (Aggressive Fibromatosis): Active Surveillance, Sorafenib/Nirogacestat Therapy, and FAP-Associated Disease
- Cervical Cancer: HPV-Driven Pathogenesis, FIGO Staging, and Stage-Based Treatment
- Cancer Survivorship Care: Late Effects, Surveillance, and Long-Term Health
- Small Cell Lung Cancer: VALG Staging, Platinum-Etoposide, Atezolizumab, and PCI Strategy